Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 30;145(5):543-546.
doi: 10.1182/blood.2024025868.

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Febe Smits  1   2   3 , Kaz Groen  1   2 , Mark-David Levin  4 , Claudia A M Stege  5 , Roel van Kampen  6 , Ellen van der Spek  7 , Yavuz M Bilgin  8 , Noortje Thielen  9 , Inger Nijhof  10 , Inge Ludwig  11 , Esther G M de Waal  12 , Yorick Sandberg  13 , Alain Kentos  14 , Gert-Jan Timmers  15 , Josien C Regelink  16 , Matthijs Westerman  17 , Koen de Heer  18 , Marie-Christiane Vekemans  19 , Nazik Durdu-Rayman  20 , Nicole C H P de Graauw  21 , Maarten R Seefat  1   2 , Niels W C J van de Donk  1   2 , Paula F Ypma  3 , Kazem Nasserinejad  5 , Sonja Zweegman  1   2
Affiliations

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Febe Smits et al. Blood. .

Abstract

The level of frailty, according to the International Myeloma Working Group frailty index, is highly dynamic during antimyeloma treatment. Dynamic frailty assessment improved the prediction of survival and early mortality compared with the prognostic value of static frailty level at baseline.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: C.A.M.S. provided consultancy and is part of the speakers bureau of Janssen, Sanofi, Takeda, and Celgene. E.v.d.S. received honoraria for educational events from Janssen. A.K. provided consultancy for Amgen, Sanofi, and Janssen-Cilag. G.-J.T. received honoraria for consultancy and travel expenses from Novartis and Janssen. M.W. received honoraria for educational events from Janssen. M.-C.V. provided consultancy for Amgen, Janssen, Celgene, Sanofi, Pfizer, GlaxoSmithKline, and Menarini and received honoraria for educational events from Amgen, Celgene, Janssen, and Takeda. P.F.Y. received honoraria for educational events from Janssen. N.W.C.J.v.d.D. received research funding from Janssen, Amgen, Celgene, Bristol Myers Squibb, Takeda, Merck, Roche, Novartis, Bayer, Adaptive, Pfizer, AbbVie, and Servier, all paid to the institution. S.Z. received research funding from Takeda, Celgene, and Janssen and participates in advisory boards of Takeda, Celgene, Janssen, Sanofi, Oncopeptides, and Amgen, all paid to the institution. The remaining authors declare no competing financial interests.

References

Publication types